Fuji Pharma Co., Ltd. (4554) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Fuji Pharma Co., Ltd.

Elan Corp.

Earth Corp.

ASKA Pharmaceutical Holdings Co., Ltd.

Zeria Pharmaceutical Co., Ltd.

Katakura Industries Co., Ltd.

Daito Pharmaceutical Co., Ltd.

CellSource Co., Ltd.

Torii Pharmaceutical Co., Ltd.

Seikagaku Corp.

SanBio Co., Ltd.

Why is Fuji Pharma Co., Ltd. ?

Weak Long Term Fundamental Strength with a 6.62% CAGR growth in Operating Profits over the last 5 years

Poor long term growth as Net Sales has grown by an annual rate of 7.08% and Operating profit at 6.62% over the last 5 years

Flat results in Jun 25

INVENTORY TURNOVER RATIO(HY) Lowest at 1.38%
INTEREST(Q) At JPY 95 MM has Grown at 43.94%
INTEREST COVERAGE RATIO(Q) Lowest at 2,133.68

With ROCE of 7.08%, it has a very attractive valuation with a 0.80 Enterprise value to Capital Employed

The stock is trading at a premium compared to its peers' average historical valuations
Over the past year, while the stock has generated a return of 12.85%, its profits have fallen by -27.9%

Underperformed the market in the last 1 year

The stock has generated a return of 12.85% in the last 1 year, much lower than market (Japan Nikkei 225) returns of 29.35%

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Fuji Pharma Co., Ltd. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Fuji Pharma Co., Ltd. for you?

Low Risk, Low Return

Absolute

Risk Adjusted

Volatility

Fuji Pharma Co., Ltd.

13.38%

0.67

26.76%

Japan Nikkei 225

28.54%

1.14

25.81%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

7.08%

EBIT Growth (5y)

6.62%

EBIT to Interest (avg)

45.26

Debt to EBITDA (avg)

2.68

Net Debt to Equity (avg)

0.46

Sales to Capital Employed (avg)

0.63

Tax Ratio

20.55%

Dividend Payout Ratio

18.00%

Pledged Shares

Institutional Holding

ROCE (avg)

6.78%

ROE (avg)

8.22%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

0.70

EV to EBIT

11.27

EV to EBITDA

6.14

EV to Capital Employed

0.80

EV to Sales

1.09

PEG Ratio

Dividend Yield

ROCE (Latest)

7.08%

ROE (Latest)

7.95%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Bullish

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

No Trend

Mildly Bullish

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

4What is working for the Company

DEBT-EQUITY RATIO (HY)

Lowest at 54.2 %

RAW MATERIAL COST(Y)

Fallen by -6.26% (YoY

DEBTORS TURNOVER RATIO(HY)

Highest at 2.85%

-22What is not working for the Company

INVENTORY TURNOVER RATIO(HY)

Lowest at 1.38%

INTEREST(Q)

At JPY 95 MM has Grown at 43.94%

INTEREST COVERAGE RATIO(Q)

Lowest at 2,133.68

NET PROFIT(Q)

At JPY 539.56 MM has Fallen at -41.42%

Here's what is working for Fuji Pharma Co., Ltd.

Debt-Equity Ratio

Lowest at 54.2 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Debtors Turnover Ratio

Highest at 2.85%

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost

Fallen by -6.26% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Fuji Pharma Co., Ltd.

Interest

At JPY 95 MM has Grown at 43.94%

period on period (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (JPY MM)

Interest Coverage Ratio

Lowest at 2,133.68

in the last five periods

MOJO Watch

The company's ability to manage interest payments is deteriorating

Operating Profit to Interest

Inventory Turnover Ratio

Lowest at 1.38% and Fallen

In each half year in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Interest

Highest at JPY 95 MM

in the last five periods and Increased by 43.94% (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (JPY MM)

Net Profit

Lowest at JPY 539.56 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (JPY MM)

Net Profit

At JPY 539.56 MM has Fallen at -41.42%

over average net sales of the previous four periods of JPY 921.06 MM

MOJO Watch

Near term Net Profit trend is negative

Net Profit (JPY MM)